cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Xilio Therapeutics Inc
1 own
3 watching
Current Price
$3.62
$-0.11
(-2.95%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
99.21M
52-Week High
52-Week High
14.86
52-Week Low
52-Week Low
1.95
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization99.21M
icon52-Week High14.86
icon52-Week Low1.95
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Xilio Therapeutics Inc do?
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Read More
How much money does Xilio Therapeutics Inc make?
News & Events about Xilio Therapeutics Inc.
Globe Newswire
2 months ago
WALTHAM, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the company will host a live virtual program on Thursday, December 1, 2022, at 12...
Globe Newswire
2 months ago
XTX202, a tumor-activated IL2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T cells and NK cells observed with no signs of vascular leak syndrome XTX301, a tumor-activated IL-12, received FDA clearance for IND ...
Globe Newswire
3 months ago
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the company will participate in a virtual fireside chat at the Cowen 6th Annual ...
Globe Newswire
1 year ago
WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq:XLO), a biotechnology company developing tumor-selectiveimmuno-oncology therapiesforpatients with cancer,today announced data from preclinical studies of XTX301, an engineered tumor-selective interleukin-12 (IL-12) ...
Frequently Asked Questions
Frequently Asked Questions
What is Xilio Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Xilio Therapeutics Inc shares?
plus_minus_icon
How can I buy Xilio Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Xilio Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Xilio Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Xilio Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Xilio Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Xilio Therapeutics Inc?
plus_minus_icon
What percentage is Xilio Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Xilio Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$3.62
$-0.11
(-2.95%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00